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Abstract
Objectives: To compare bleeding patterns for 12 months continuous use of a contraceptive ring [contraceptive vaginal ring (CVR)] and pill
[combined oral contraceptive (COC)] on a menstrually signaled regimen and the effectiveness of 4 days “treatment withdrawal” to stop
bleeding.
Study design:Women, 66 to each group, were randomized to continuous use of a CVR (15 mcg ethinyl estradiol/150 mcg etonogestrel) or a
low-dose pill (20 mcg ethinyl estradiol/100 mcg levonorgestrel) for 360 days on a menstrually signaled regimen. Bleeding/spotting days,
daily use of ring or pill, was recorded. Endpoint was the total number of bleeding/spotting days for each method over four 90-day reference
periods (RP) plus the analysis of bleeding patterns using modified World Health Organization criteria.
Results: There was a reduction in the mean (±S.D.) number of bleeding/spotting days from RP1 (CVR 14.2±10; pill 16.6±10.9) to RP4
(CVR 8.8±9.6; pill 8.8±9.1). Fifteen percent of CVR and 4% COC users experienced amenorrhea or infrequent bleeding throughout the
study. Amenorrhea increased over time (RP1 vs. RP4: CVR 10% vs. 21% and COC 2% vs. 30%). Compliance with the menstrually signaled
regimen was poor. Ceasing hormones for 4 days stopped a bleeding episode within 5 days in the majority of episodes and many stopped
spontaneously.
Conclusion: Bleeding patterns with continuous use of the CVR and COC are similar and improve over 1 year of use. The unpredictability,
but short duration, of bleeding episodes should be stressed during counseling.
Implication: This information for clinicians and women about breakthrough bleeding patterns with use of a CVR or combined pill over
12 months using a menstrually signaled regimen will give women an indication of what to expect with continuous use.
© 2014 Elsevier Inc. All rights reserved.
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1. Introduction
A large global survey in 2012 found that 50% of women
wanted flexibility to determine when their menstruation
would start, with 36%wanting not to bleed at all or only once
every 2–3 months, while for 44%, regular bleeding was
important [1]. Other surveys have shown that 30–50% prefer
amenorrhea, 40% prefer to bleed 2–4 times a year and 40%
want regular monthly menses [2,3]. An 8-country survey
found that 58% of women would accept irregular bleeding
initially if they had fewer periods over time [4].
A number of studies have looked at extended use of
combined oral contraceptives (COCs) and NuvaRing,
Contraception xx (2014) xxx–xxx
☆ Declaration of interest: The CVRs used in the study were provided by
MSD and the COC was provided by Bayer Healthcare. Neither company was
involved in any aspect of the design, execution or analysis of results. Edith
Weisberg has provided expert opinion for MSD and Bayer Healthcare, has
been supported to attend conferences by Bayer Healthcare and has obtained
research funding for investigator-initiated research from both companies.
Gabriele SusanneMerki-Feld has financial relationships (as a lecturer, member
of advisory boards and/or consultant) with MSD and Bayer-Schering Pharma,
AG. Ian Fraser has been a member of Advisory Boards and given sponsored
lectures for Bayer Healthcare, MSD, Daiichi-Sankyo and Vifor Pharma, and
has received occasional research funding from these companies.
☆☆ Clinical trial registration ACTRN12609000391279.
⁎ Corresponding author. Sydney Centre for Reproductive Health
Research, Family Planning New South Wales, 328-336 Liverpool Road,
Ashfield,NSW2131,Australia. Tel.: +61-2-8752-4342; fax: +61-2-8752-4394.
E-mail address: edithw@fpnsw.org.au (E. Weisberg).
http://dx.doi.org/10.1016/j.contraception.2014.10.006
0010-7824/© 2014 Elsevier Inc. All rights reserved.
mainly for 84 or 91 days [5,6]. A 12-month randomized
study in American women compared the bleeding profile of
a flexible extended regimen of ethinylestradiol/drospirenone
with the standard 24/4 day regimen [7]. Although two other
studies compared scheduled 3- or 4-day hormone-free
intervals in women using 6 months continuous combined
hormonal contraception [8,9], none addressed “menstrually
signaled” regimens and no studies provide a detailed analysis
of such regimens or a made a comparison between different
delivery programs for combined hormonal contraceptives.
We report on a detailed analysis of bleeding patterns in
women randomly assigned to 12 months continuous use of a
vaginal ring [contraceptive vaginal ring (CVR)] or a low-
dose COC on a menstrually signaled regimen.
In this study, our primary comparison was focused on the
number of bleeding or spotting days between women using a
combined CVR releasing 15 mcg ethinyl estradiol and
150 mcg etonogestrel daily vs. a COC containing 20 mcg
ethinyl estradiol and 100 mcg levonorgestrel continuously
over 12 months on a menstrually signaled regimen that
required women to remove the CVR or stop their pill on the
fifth day if a bleeding/spotting episode persisted beyond
4 days and to restart after a 4-day interval. We also compared
the acceptability of and women’s satisfaction with the two
treatments and the impact of 4 days cessation of treatment on
bleeding episodes irrespective of mode of administration.
2. Methods and materials
Women aged between 18 and 45 years requesting
contraception were recruited through Family Planning New
South Wales clinics in Sydney, Australia, the telephone
information service, the Research Centre database and
Facebook advertisements. Women with no contraindications
who were willing to use hormonal contraception continu-
ously for 12 months and maintain a menstrual diary were
enrolled after giving informed consent. Women could be
new users, restarters or switchers and they needed to accept
randomization. Exclusion criteria were current pregnancy,
undiagnosed intermenstrual bleeding, body mass index of
N30 kg/m2, risk factors or history of thromboembolism or
cardiovascular disease, blood pressure of N149/90 mmHg,
smokers aged ≥35 years, current users of enzyme inducing
drugs or users of injectable contraception within the last
6 months.
At the screening visit, women completed a menstrual
attitudes questionnaire, based on the “ARHP Menstrual
Attitudes Questionnaire” [10] including their preference for
frequency of menses. A physical examination including vital
signs and gynecological examination were performed and a
Pap smear was taken, if there was no smear within the past
2 years.
Eligible women were randomized according to a
computer-determined scheme to either continuous CVR
use with replacement of a new ring every 28 days or daily
active COC pill ingestion. The allocation, contained in a
consecutively numbered sealed opaque envelope, was
opened by the subject at the randomization visit. The
women inserted the ring or started the pill on the first day of
their next period and completed a daily paper diary to record
whether the ring was in situ or a pill was taken and any
bleeding/spotting occurred. If a bleeding/spotting episode
recurred within 14 days of a previous break in contraceptive
use, women were asked to contact the research coordinator
for further instructions. Participants were seen at the
Research Centre 2, 4, 6 and 12 months after starting their
medication. The research coordinator telephoned partici-
pants at 1, 3 and 5 months to ensure that they were
completing the daily diary and correctly following instruc-
tions for ceasing medication if a bleeding/spotting episode
exceeded 4 days.
At each clinic visit, menstrual diaries were checked for
compliance and clarification, and weight and vital signs were
checked. At conclusion or withdrawal, physical and
gynecological examinations were again carried out. The
menstrual questionnaire was readministered.
The primary outcome for the study was the difference in
mean number of bleeding/spotting days between the groups
over time. Secondary outcomes were the proportion of
women who reported a particular bleeding pattern and the
number of days it took for a bleeding episode to stop
following cessation of hormones.
The power calculation indicated that 70 women would be
required for each arm to detect a difference of 0.5 standard
deviations in our primary outcome (mean number of days of
bleeding/spotting) with 90% power and significance level
of 0.05.
Bleeding/spotting episodes and duration were analyzed in
four 90-day reference periods (RP). For each RP, the number
of bleeding/spotting days combined and separately was
calculated for each subject according to group assignment.
The mean number of bleeding/spotting days was then
compared between groups and over time. For each
individual, the bleeding diary was converted to an Excel
graph for visual comparison of bleeding patterns. The
bleeding patterns for each RP were also assessed according
to World Health Organization (WHO) criteria [11]. We
calculated the percentage of women who reported a
particular bleeding pattern.
The analysis was carried out using the SAS 9.3 program.
The study was approved by the Family Planning New
South Wales Ethics Committee, and fully informed
consent was obtained. The clinical trial was registered
(ACTRN12609000391279).
3. Results
Of 144 women screened, 5 were screen failures and 7
withdrew before randomization (Fig. 1). Sixty-six women
were assigned to each method. One woman in each group
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withdrew before starting the medication (Fig. 1). Demo-
graphic characteristics of the participants are demonstrated
in Table 1.
Among women using the COC, 26 admitted to missing at
least one pill, mainly in RP1 and RP2. In most instances
(71%), this did not result in breakthrough bleeding (BTB)
but occasionally resulted in 1–3 days of spotting, which
stopped spontaneously irrespective of RP. Missing a pill 2 or
3 times in a single RP did not appear to provoke BTB.
Women missing consecutive pills were more likely to bleed
but stopped spontaneously within 2–3 days. The CVR was
expelled in two users, one started bleeding immediately in
RP2, while the other was uncertain how long the ring had
been out but she did not bleed. Six women removed their
ring for 1 day at different times but did not have BTB,
although one woman who removed her ring for 2 days in
RP4 bled for 3 days.
We found little difference in the mean number of days of
bleeding/spotting per RP between the two groups (p=.27)
(Fig. 2). However, the mean number of days decreased from
RP1 to RP4 for both methods (16–9 days for the CVR, and
14–9 days for the COC; pb.001). Similar results were found
for these two comparisons for bleeding only (p=.55 and
pb.001), spotting only (p=.26 and pb.001) and number of
episodes (p=.30 and pb.001), a trend already apparent at
RP2 (Table 2).
Adherence to the menstrually signaled regimen was
inconsistent based on diaries, with women complying
precisely with instructions for stopping medication after
4 days of bleeding in only 42% of episodes. Overall, in
compliant episodes, 50% of women had ceased bleeding/
spotting by 4 days after stopping medication and 91% had
Number screened
144
Randomised to pill - 66 Randomised to ring - 66
Withdrawn - 19 Completed - 46
0   11
RP completed No women
1  4
2 2
3 2
Reasons for withdrawal
Unacceptable bl/sp 7           
Headaches                      1
Moved 1
LTF 1
Acne 2
Desire for pregnancy 1
Nausea  2
Lactose intolerance 1
Mood swings  2
Weight gain  0
Pregnant 2
Dysmenorrhoea 1
Withdrawn - 18
RP completed    No women
0   4
1      6
2 4
3 4
Reasons for withdrawal
Unacceptable bl/sp 2
Mood swings   2
Headaches 2
Weight gain 1
Pregnant 0
Desire for pregnancy 2
Moved 1
LTF 3
DVT 1
Ring uncomfortable      1
Screen failures
5
Randomised did 
not start 1
Randomised did 
not start 1
Withdrew before 
randomisation 7
Completed - 47
Fig. 1. Study flow chart.
Table 1
Demographics of participants.
COC (n=54) CVR (n=61)
n (%) n (%)
Age group b20 6 (11) 6 (10)
20–24 24 (44) 22 (36)
25–29 15 (28) 20 (33)
30–4 6 (11) 6 (10)
≥35 3 (6) 7 (11)
Highest level of education Secondary 10 (19) 10 (16)
Technical/
vocational
9 (17) 12 (20)
University 35 (65) 39 (64)
Cultural background Caucasian 40 (74) 52 (85)
Other 14 (26) 9 (15)
Total number
of pregnancies
0 40 (74) 45 (74)
1 5 (9) 5 (8)
≥2 9 (17) 11 (18)
Number of living childrena 0 46 (85) 51 (85)
1 2 (4) 1 (2)
≥2 6 (11) 8 (13)
a Information missing for one woman in CVR group.
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ceased by 7 days after stopping (and restarting). Of 73
episodes of bleeding/spotting, which stopped spontaneously,
46 (63%) lasted 4 days or less and 26 (35%) stopped between
5 and 8 days. None lasted longer than 8 days (Table 3).
Nine women withdrew because of unacceptable bleeding
patterns: 5 COC users before completing RP1 and 2 after
completing RP2; 1 CVR user after RP1 and 1 after RP3. Other
reasons for prematurewithdrawalwere similar to those reported
in other combined hormonal contraceptive studies (Fig. 1).
When the data were analyzed using the WHO criteria
[11], a higher proportion of COC users had frequent bleeding
while a higher proportion of CVR users had more infrequent
bleeding (Table 3).
When asked at completion or early withdrawal from the
study, the majority of women preferred continuous use of
hormonal contraception: 41 (93%) CVR users and 42 (84%)
COC users. The majority of women [60 (73%)] were very
satisfied or somewhat satisfied [13 (14%)] with the regimen.
The major reasons for liking continuous use were ease of use
and infrequent or no bleeding. No period pain, headaches or
premenstrual syndrome were also advantages for some
women. The unpredictability of bleeding was the factor most
disliked by half the women who were otherwise happy with
the regimen.
4. Discussion
The current study randomly compares two delivery
methods of combined hormonal contraception used on a
menstrually signaled regimen over 12 months. It reports on
bleeding/spotting days and also bleeding episodes and
patterns according to the modified WHO criteria.
The vaginal bleeding patterns associated with continuous
estrogen–progestogen or progestogen-alone contraceptive
regimens are quite different from spontaneous cyclical
menstrual patterns and have required new approaches to
description and analysis. Initial discussions on such a
concept began in the early 1970s [12]. WHO sponsored a
major international study in 10 developing and developed
countries [13], taking into account the patient perception of
experienced patterns, including duration and variation in
flow — the “comfort” factors in bleeding experience.
A significant later contribution of this program was the
development of a series of “clinically relevant bleeding
patterns” determined from the appeal and tolerance of
particular bleeding patterns by women in large-scale WHO
clinical trials. The program also assessed menstrual patterns
in a very large database of untreated women and refined their
analysis and definitions of clinically relevant bleeding
patterns based on these data [11].
More recently, Mishell and colleagues have drawn
attention to the continuing need for a uniform approach to
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Fig. 2. Mean number of bleeding/spotting days according to RP for women allocated to CVR or COC.
Table 2
The number of days elapsed for bleeding/spotting to stop after ceasing
hormonal contraceptive medication for 4 days.
Number days to stop bleeding
after stopping medication
Number of
episodes
Percentage
(%)
Cumulative
percentage (%)
0a 83 17
1 16 3
2 24 5
3 38 8
4 84 17 50
5 101 21 71
6 73 15
7 31 6 92
8 22 5
9 8 2
10 7 1
11 3 1
12 0
13 0
14 1 0.2 100
a Ceased at time they stopped medication.
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descriptions and analysis of bleeding patterns in women
using hormonal contraceptive preparations [14,15]. The
International Federation of Gynecology and Obstetrics
(FIGO) has established a FIGO Menstrual Disorders
Standing Committee who have strongly recommended new
and uniform approaches to nomenclature and definitions
around normal and spontaneously abnormal uterine bleeding
[16]. Hence, it is clear that there are still issues around the
description of bleeding patterns that remain to be addressed,
especially in terms of community perception and women’s
comfort and tolerance of particular patterns. However, the
currently endorsed international approach does allow
valuable, hard, scientific comparison of basically unpredict-
able and highly variable patterns of moderate bleeding and
very light bleeding (“spotting”) in groups of women using
differing hormonal contraceptive preparations.
Such detailed analyses can support doctors in counsel-
ing women about what to expect when they start
continuous regimens.
Although individual bleeding patterns were variable and
unpredictable for both methods, the mean number of
bleeding/spotting, bleeding or spotting days and number of
episodes were similar for the two methods, although there
was a significant decrease for all these parameters between
RP1 and RP4 for both. This could be due, in part, to women
with more problematic bleeding withdrawing from the study,
although study of individual patterns does not support this. It
also confirms experience from other studies that, over time,
bleeding patterns in women using continuous hormonal
contraception improve substantially [7–9].
There appeared to be subtle differences in bleeding
patterns between the two methods. CVR users experienced
more RPs with no bleeding and more RPs with infrequent
but prolonged bleeding, whereas COC users tended to have
more RPs with short-light spotting episodes (Table 3).
Surveys indicate that approximately 36% of women in
many countries do not want to bleed at all or only once every
2 or 3 months [1,2]. In our study, 44% preferred no bleeding
at all. What is important to many women is how manageable
their bleeding is, impinging as little as possible on daily
activities and quality of life. The majority of women prefer to
have fewer bleeding days and less heavy bleeding [1,2,17].
Only 37% wanted monthly bleeding [18]. Around 30% of
women feel that menstrual bleeding has a severe negative
impact on their daily life [2,17]. In a recent Swiss survey,
80% of the participants wanted fewer bleeding days while
using a contraceptive [18].
Although compliance with the regimen of stopping
medication for 4 days on the fifth day of a bleeding/spotting
episode was inconsistent, an episode persisting for more than
4 days was likely to stop spontaneously for many women
within a reasonable time (4–8 days). Among women who
stopped their combined hormonal contraceptive for 4 days,
two thirds of bleeding/spotting episodes stopped within the
next 5 days, useful information for women wishing to use
continuous combined methods.
This was an open-label randomized study with two well-
matched groups. The research coordinator was in monthly
contact with the subjects to encourage completion of the
menstrual diary. Although the study relied on self-reporting,
it is likely that this regular contact ensured a reasonably
accurate completion of the menstrual diaries, providing
reliable data on bleeding patterns. It is possible that using a
higher-dose COC may have provided better cycle control but
we decided on a 20EE/100LNG COC to make it reasonably
comparable in ethinyl estradiol serum levels to those
achieved with the CVR [11].
The bleeding pattern with extended regimens may vary
with estrogen and progestogen dosage and delivery route
[17]. Most studies demonstrate that the total number of
bleeding days with extended hormonal contraceptive cycles
decreases over time. However, the high rate of unscheduled,
albeit light, bleeding compromises this advantage and may
be a cause for the often high dropout rate [4,6,11,16,18]. In
menstrually signaled regimens, recommending a break
varying between 3 and 7 days to stop longer bleeding
episodes [11,16], dropout rates are high even though these
regimens result in fewer bleeding days. The large number of
women using these regimens, who were not compliant in our
and other studies, indicate that detailed counseling is needed.
In this study, the number of baseline bleeding/spotting
days and their decrease over the four RP with the 20EE/
100LNG pill were in the range observed in other studies with
20 and 30 mcg ethinyl estradiol/levonorgestrel combinations
in 84/7 nonsignaled regimens [7–9]. The high dropout rate of
more than 40% in 84/7 studies may have biased the low
Table 3
Percentage of women with different bleeding patterns per 90-day RP according to CVR or COC use.
CVR COC CVR COC CVR COC CVR COC
RP1 RP1 RP2 RP2 RP3 RP3 RP4 RP4
No % No % No % No % No % No % No % No %
Frequent bleeding, 4 episodes 1 (2) 3 (6) 0 3 (6) 0 2 (4) 0 0
Infrequent bleeding, b2 episodes 14 (23) 10 (19) 18 (37) 14 (28) 14 (29) 7 (15) 15 (32) 6 (13)
No bleeding 6 (10) 1 (2) 7 (13) 4 (8) 17 (35) 12 (25) 10 (21) 14 (30)
Prolonged bleeding, ≥10 days 21 (34) 21 (39) 19 (39) 11 (22) 8 (16) 3 (2) 15 (32) 6 (13)
Irregular bleeding, range of lengths of bleeding-free intervals exceeding
N17 days
3 (5) 2 (4) 3 (6) 3 (6) 2 (4) 4 (8) 0 2 (4)
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number of bleeding/spotting days reported in these trials. Our
finding that a 4-day break in hormone use stops bleeding in
two thirds of episodes within 5 days may be helpful in
increasing continuation rates, especially during the initial
months. The goal of most women participating in extended
cycle regimens is a desire to achieve amenorrhea. After 1 year,
continuous use of a 20 mcg ethinyl estradiol/100 mcg
levonorgestrel COC Miller reported amenorrhea during RP4
in 72% of users [18]. In our study, the rate of amenorrhea was
much lowerwith both study preparations. However, the sumof
amenorrhea and infrequent bleeding, both convenient bleeding
patterns, was around 60% for both the ring and the pill.
5. Conclusion
This study provides information on bleeding patterns to
be expected using these regimens. Continuous CVR use
appears to result in infrequent but prolonged bleeds every 2–
3 months while continuous low-dose COC use appears to
produce more frequent, but shorter spotting episodes.
Acknowledgements
Our thanks to Sarah Robertson, the research coordinator
whose assiduous follow-up of participants accounts for the
success of this study.
References
[1] Szarewski A, von Stenglin A, Rybowski S. Women’s attitudes towards
monthly bleeding: Results of a global population-based survey. Eur J
Contracept Reprod Health Care 2012;17(4):270–83.
[2] den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of
menstrual bleeding in relation to reproductive status, oral contraceptive
use, and hormone replacement therapy use. Contraception 1999;59
(6):357–62.
[3] Ferrero S, Abbamontea LH, Giordano M, Allesandr F, Anserini P,
Remorgida V, et al. What is the desired menstrual frequency of women
without menstruation-related symptoms? Contraception 2006;73
(5):537–41.
[4] Hooper DJ. Attitudes, awareness, compliance and preferences among
hormonal contraception users: A global, cross-sectional, self-
administered, online survey. Clin Drug Investig 2010;30(11):749–63.
[5] Davis MG. A look at the long-term safety of an extended-regimen OC.
J Fam Pract 2010;59(5):E9–13.
[6] Wiegratz I, Stahlberg S,Manthey T, SangerN,MittmanK, LangeE, et al.
Effect of extended-cycle regimen with an oral contraceptive containing
30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety,
acceptance and contraceptive efficacy. Contraception 2011;84
(2):133–43.
[7] Jensen JT, Garie SG, Trummer D, Elliesen J. Bleeding profile of a
flexible extended regimen of ethinylestradiol/drospirenone in US
women: An open-label, three-arm, active-controlled, multicenter
study. Contraception 2012;86(2):110–8.
[8] Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of
occurrence and management of breakthrough bleeding during an
extended oral contraceptive regimen. Am J Obstet Gynecol 2006;195
(4):935–41.
[9] Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of
extended oral contraceptive regimens with a shortened hormone-free
interval to manage breakthrough bleeding. Contraception 2004;70
(4):281.
[10] Menstruation and menstrual suppression: What women and healthcare
providers really think. , www.arhp.org/menstruation2003 [accessed
15/10/2008].
[11] Belsey EM, Pinol AP. Menstrual bleeding patterns in untreated
women. Task Force on Long-Acting Systemic Agents for Fertility
Regulation, World Health Organization. Contraception
1997;55:57–65.
[12] Rodriguez G, Faundes-Latham A, Atkinson LE. An approach to the
analysis of menstrual patterns in the critical evaluation of contracep-
tives. Stud Fam Plann 1976;7:42–51.
[13] Snowden R, Christian B. Patterns and perceptions of menstruation (A
World Health Organization international study). London: Croom
Helm; 1983339.
[14] Mishell DR, Guillebaud J, Westhoff C. Recommendations for
standardization of data collection and analysis of bleeding in combined
hormone contraceptive trials. Contraception 2007;75(1):11–5.
[15] Fraser IS, Critchley HOD, Munro MG, Broder M. A process designed
to lead to international agreement on terminologies and definitions
used to describe abnormalities of uterine bleeding. Fertil Steril
2007;87:466–76.
[16] Edelman A, Lew R, Ciak C, Nichols M, Jensen J. Acceptability of
contraceptive-induced amenorrhea in a racially diverse group of US
women. Contraception 2007;75(6):450–3.
[17] Merki-Feld GS, Breitschmid N, Seifert B, Kreft M. A survey on Swiss
women’s preferred menstrual/withdrawal bleeding pattern over
different phases of reproductive life and with use of hormonal
contraception. Eur J Contracept Reprod Health Care 2014;19
(4):266–75.
[18] Miller L, Hughes JP. Continuous combination oral contraceptive pills
to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol
2003;101(4):653–61.
6 E. Weisberg et al. / Contraception xx (2014) xxx–xxx
